Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention

• References

• 1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 2 Ansell J. Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism? New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012; 125: 165-170.
• 3 Kmietowicz Z. Boehringer promoted off-label drug to patients, finds watchdog. Br Med J 2011; 343: d8251.
• 4 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
• 5 de laFouchardière C, Flechon A, Droz JP. Coagulopathy in prostate cancer. Neth J Med 2003; 61: 347-354.
• 6 Federici TJ. Leuprolide acetate and central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2007; 38: 497-499.
• 7 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
• 8 Jönsson KM, Wieloch M, Sterner G. et al. Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden. Thromb Res 2011; 128: 341-345.
• 9 Stangier J, Rathgen K, Stähle H. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
• 10 Baker DE. Loperamide: a pharmacological review. Rev Gastroenterol Disord 2007; 07 (Suppl. 03) S11-18.
• 11 Jungbauer L, Dobias C, Stöllberger C. et al. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost 2010; 08: 2069-2070.
• 12 Crowe A, Wong P. Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport. Toxicol Appl Pharmacol 2003; 193: 127-137.
• 13 Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011; 365: 2039-2040.
• 14 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
• 15 Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 04: 967-970.
• 16 Reynolds S, Parra D, Rosenstein RS. Letter by Reynolds et al regarding article, „Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial”. Circulation 2012; 125: e291.
• 17 Kulik A, Saltzman MB, Morris JJ. Dabigatran after cardiac surgery: caution advised. J Thorac Cardiovasc Surg 2011; 142: 1288.
• 18 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
• 19 Pengo V, Crippa L, Falanga A. et al. Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.